ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company based in Newtown Square, Pennsylvania, focused on developing and commercializing precision oncology medicines. Its lead candidate, firmonertinib, is an oral, brain-penetrant, mutation-selective EGFR tyrosine kinase inhibitor licensed from Shanghai Allist Pharmaceuticals, with which ArriVent holds ex-China rights. The drug is already approved in China for certain EGFR-mutant non-small cell lung cancer (NSCLC) indications and was being advanced globally for EGFR exon 20 insertion and PACC mutations.
Beyond firmonertinib, ArriVent is building an antibody-drug conjugate (ADC) pipeline, including ARR-217, a CDH17-targeted ADC partnered with Lepu Biopharma for gastrointestinal cancers, and ARR-002, a dual-target MUC16/NaPi2b ADC. Investors follow the stock primarily for the firmonertinib data catalysts and the company's emerging ADC optionality. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, AVBP has fallen approximately 45%, from a closing price of $28.45 on September 25, 2026 to around $15.70 in recent trading. The decline was abrupt: on October 6, 2026, shares dropped about 47% in a single session, from $28.46 to a close of $15.09, touching a 52-week low near $12.09 intraday on unusually heavy volume.
The quarterly trend tells a similar story. Through July, August, and September, the stock traded mostly in a $28 to $31 range as investors positioned ahead of the pivotal FURVENT readout. Because the stock was essentially range-bound before the early-October announcement, the quarterly decline of roughly 45–50% is almost entirely attributable to the same trial outcome that drove the 30-day move.
The dominant catalyst was the failure of the global Phase 3 FURVENT trial. On October 6, 2026, ArriVent announced that firmonertinib monotherapy did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review in previously untreated patients with EGFR exon 20 insertion-mutated NSCLC. The 240 mg dose achieved median PFS of 11.0 months versus 9.5 months for platinum-based chemotherapy, with a hazard ratio of 0.75 that narrowly missed statistical significance.
Analysts attributed the miss in part to a stronger-than-expected chemotherapy control arm, which delivered roughly 9.5 months of PFS versus anticipated estimates of about 7.5 to 8 months. Secondary endpoints favored firmonertinib, including investigator-assessed PFS of 11.1 versus 7.1 months and a confirmed objective response rate of 60% versus 33%, with no new safety signals.
The news triggered a sharp re-rating. Multiple firms lowered their price targets, with Jefferies, Truist, and Guggenheim each moving their targets from around $45 to $18, and analysts removed the exon 20 insertion indication from their valuations. The stock subsequently staged a partial recovery before the late-October ESMO 2026 meeting, where ArriVent presented encouraging Phase 1 data for its ARR-217 ADC, showing a 44.8% objective response rate at the 6 mg/kg dose in heavily pretreated colorectal cancer patients.
For most of the quarter, AVBP traded sideways in the $28 to $31 range, reflecting a balance between optimism over the firmonertinib readout and overhangs such as a $250 million at-the-market offering program announced in May 2026. The company also reported second-quarter 2026 results in August, widening its net loss as research and development spending rose.
The quarter's defining event was the FURVENT failure, which removed a key near-term value driver and forced a fundamental reassessment of the lead program. That reassessment redirected investor attention toward firmonertinib's second pivotal opportunity, the ALPACCA trial in EGFR PACC-mutant NSCLC, and toward the ADC pipeline, including ARR-217 and ARR-002, the latter of which began dosing its first patient in October.
Looking ahead, the key question is how ArriVent reprioritizes its pipeline after the FURVENT outcome. Investors will monitor the company's review of the complete FURVENT dataset and any update on the future development path for firmonertinib. The ALPACCA Phase 3 trial in EGFR PACC-mutant NSCLC remains the drug's principal remaining late-stage opportunity.
On the ADC side, further ARR-217 Phase 1b dose-optimization data is expected in 2027, and the early clinical progress of ARR-002 will be closely watched. Financial factors also matter: a clinical-stage company with no product revenue faces ongoing cash burn, and its financing strategy will be important given the at-the-market program and rising R&D costs. Upcoming quarterly earnings and any regulatory or partnership updates will further shape the outlook. From what I see, monitoring these catalysts closely remains essential.
In my analysis of names like AVBP, I often turn to Tickeron’s platform for additional perspectives. The AI Daily Buy/Sell Signals feature helps me review recent patterns and compare performance across similar clinical-stage companies. It provides a practical way to layer quantitative signals onto fundamental research without replacing it. This approach has become a regular part of how I evaluate volatile biotech opportunities.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 50-day moving average for AVBP moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AVBP as a result. In 30 of 36 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for AVBP entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for AVBP's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for AVBP just turned positive on November 09, 2026. Looking at past instances where AVBP's MACD turned positive, the stock continued to rise in 19 of 22 cases over the following month. The odds of a continued upward trend are 86%.
Following a +5.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVBP advanced for three days, in 127 of 160 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
AVBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.833) is normal, around the industry mean (3.596). P/E Ratio (-3.842) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. AVBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology